Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Comparing Ticagrelor Versus Clopidogrel on Microcirculation
- Conditions
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Dong-A University
- Target Recruit Count
- 120
- Registration Number
- NCT02618733
- Locations
- 🇰🇷
Department of Internal Medicine,Dong-A University College of Medicine, Busan, Korea, Republic of
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1900
- Registration Number
- NCT02617290
- Locations
- 🇫🇷
Institut de Cardiologie - USIC - Hôpital Pitié-Salpêtrière, Paris, France
Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
- Conditions
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02612480
- Locations
- 🇳🇱
Intensive Care Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Zainidip in Renal Artery Stenosis
- Conditions
- Interventions
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Lee's Pharmaceutical Limited
- Target Recruit Count
- 149
- Registration Number
- NCT02594410
- Locations
- 🇨🇳
Fuwai Hospital, Beijing, China
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT02587260
- Locations
- 🇨🇭
Inselspitäl University Medical Center, Bern, Switzerland
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇮🇹Policlinico San Matteo, Pavia, Italy
The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Michael Wolzt, Prof. MD
- Target Recruit Count
- 24
- Registration Number
- NCT02580149
- Locations
- 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria
COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS
- Conditions
- Interventions
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02578537
- Locations
- 🇨🇳
Shenyang Northern Hospital, Shenyang, Liaoning, China
Targeting Platelets in Chronic HIV Infection
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 27
- Registration Number
- NCT02578706
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 101
- Registration Number
- NCT02565693
- Locations
- 🇳🇱
Haaglanden MC, Den Haag, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Netherlands
🇳🇱Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 22
- Registration Number
- NCT02560688
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.